Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
>
Ernexa's ERNA-101 Shows 100% Survival in Ovarian Cancer Preclinical Data
Ernexa's ERNA-101 Shows 100% Survival in Ovarian Cancer Preclinical Data
Read also
Global Economic Impact: Tuberculosis Costs the World $1.35 Trillion a Year
New research reveals tuberculosis costs the world $1.35 trillion annually, draining 0.8% of global economic potential and heavily impacting poorer nations.
FDA Grants Fast Track Designation to Apnimed's Sleep Apnea Therapy AD109
Apnimed receives FDA Fast Track designation for AD109, a first-in-class oral pharmacologic candidate designed to treat obstructive sleep apnea at night.
Clinical Trial Tests Stem Cell Infusion to Stabilize Alzheimer's Disease
A new clinical trial evaluates whether a single mesenchymal stem cell infusion combined with standard therapies can stabilize early Alzheimer's disease.
Preclinical Models Prove Crucial for Establishing Antibiotic PK/PD Targets
Experts emphasize the vital role of preclinical in vitro and animal models in establishing antibiotic PK/PD targets and the need to consider host factors.
